Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of RO7239958 in Healthy Volunteers and Chronic Hepatitis B
NCT03762681Phase 1Terminated
- Sponsor
- Roche
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of RO7239958 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events up to 16 months, Number of Participants With Clinically Significant Changes in Vital Signs up to 16 months and 3 more. Started Dec 2018; status: terminated.
02
Drugs
RO7239958
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03762681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762681.